美托洛尔联合厄贝沙坦氢氯噻嗪治疗老年重症心力衰竭临床观察  

Clinical Observation of Metoprolol Combined with Irbesartan and Hydrochlorothiazide in the Treatment of Severe Heart Failure in the Elderly Patients

作　　者：张液 ZHANG Ye(Fudan University Affiliated Zhongshan Hospital Wusong Hospital,Shanghai,China 200940)

机构地区：[1]复旦大学附属中山医院吴淞医院,上海200940

出　　处：《中国药业》2023年第S02期63-65,共3页China Pharmaceuticals

摘　　要：目的探讨美托洛尔联合厄贝沙坦氢氯噻嗪治疗老年重症心力衰竭的临床疗效。方法选取医院2021年1月至2022年1月收治的老年(>60岁)重症心力衰竭患者62例,随机分为对照组和观察组,各31例。对照组患者给予常规治疗,观察组患者给予美托洛尔联合厄贝沙坦氢氯噻嗪,两组患者均治疗1个月。结果观察组的总有效率为96.77%,显著高于对照组的77.42%(P<0.05);观察组的1年内存活率为93.55%,显著高于对照组的67.74%(P<0.05)。治疗后,观察组患者的左室射血分数和射血分数均显著高于对照组,美国纽约心脏病学会(NYHA)心功能分级显著低于对照组(P<0.05);观察组患者的6 min步行距离显著长于对照组(P<0.05),脉搏输出量显著多于对照组(P<0.05)。观察组和对照组患者治疗期间的不良反应发生率相当(3.23%比9.68%,P>0.05)。结论美托洛尔联合厄贝沙坦氢氯噻嗪治疗老年重症心力衰竭的临床疗效良好,可加速患者的心功能恢复,延长生存时间,且安全性高。Objective To investigate the clinical efficacy of metoprolol combined with irbesartan hydrochlorothiazide in the treatment of severe heart failure in the elderly patients.Methods A total of 62 elderly(>60 years old)patients with severe heart failure admitted to the hospital from January 2021 to January 2022 were randomly divided into the control group and the observation group,with 31 cases in each group.The control group was given routine treatment,while the observation group was given metoprolol combined with irbesartan hydrochlorothiazide.Both groups of patients were treated for one month.Results The total effective rate in the observation group was 96.77%,which was significantly higher than 77.42%in the control group(P<0.05).The one-year survival rate in the observation group was 93.55%,which was significantly higher than 67.74%in the control group(P<0.05).After treatment,the left ventricular ejection fraction and ejection fraction in the observation group were significantly higher than those in the control group,and the New York Heart Association(NYHA)cardiac function grading in the observation group was significantly lower than that in the control group(P<0.05).The 6-min walking distance in the observation group was significantly longer than that in the control group(P<0.05),and the pulse output in the observation group was significantly higher than that in the control group(P<0.05).The incidence of adverse reactions during treatment was comparable between the observation group and the control group(3.23%vs.9.68%,P>0.05).Conclusion Metoprolol combined with irbesartan and hydrochlorothiazide is effective in the treatment of severe heart failure in elderly patients,which can accelerate the recovery of heart function,prolong survival time,and have high safety.

关 键 词：老年人 重症心力衰竭 美托洛尔 厄贝沙坦氢氯噻嗪 心功能 临床疗效 

分 类 号：R969.4[医药卫生—药理学] R972[医药卫生—药学]